AIM: To evaluate the influence of baseline maximum standardized uptake value (SUVmax) on survival in a cohort of patients, undergoing positron emission tomography-computed tomography (PET-CT) scan for esophageal carcinoma. METHODS: The pre-treatment SUVmax numeric reading was determined in patients with confirmed esophageal or junctional cancer having PET-CT scan during the time period 1(st) January 2007 until 31(st) July 2012. A minimum follow up of 12 mo was required. Patients were subdivided into quartiles according to SUVmax value and the influence of SUVmax on survival was assessed using univariate and multivariate analysis. The following pre-treatment factors were investigated: patient characteristics, tumor characteristics and planned treatment. RESULTS: The study population was 271 patients (191 male) with esophageal or junctional carcinoma. The median age was 65 years (range 40-85) and histologic subtype was adenocarcinoma in 197 patients and squamous carcinoma in 74 patients. The treatment intent was radical in 182 and palliative in 89 patients. SUVmax was linked to histologic subtype (P = 0.008), tumor site (P = 0.01) and Union for International Cancer Control (UICC) stage (P < 0.001). On univariate analysis, prognosis was significantly associated with SUVmax (P = 0.001), T-stage (P < 0.001) and UICC stage (P < 0.001). On multivariate analysis, only T-stage and UICC stage remained significant. CONCLUSION: Pretreatment SUVmax was not a useful marker in isolation for determining prognosis of patients with esophageal carcinoma.
AIM: To evaluate the influence of baseline maximum standardized uptake value (SUVmax) on survival in a cohort of patients, undergoing positron emission tomography-computed tomography (PET-CT) scan for esophageal carcinoma. METHODS: The pre-treatment SUVmax numeric reading was determined in patients with confirmed esophageal or junctional cancer having PET-CT scan during the time period 1(st) January 2007 until 31(st) July 2012. A minimum follow up of 12 mo was required. Patients were subdivided into quartiles according to SUVmax value and the influence of SUVmax on survival was assessed using univariate and multivariate analysis. The following pre-treatment factors were investigated: patient characteristics, tumor characteristics and planned treatment. RESULTS: The study population was 271 patients (191 male) with esophageal or junctional carcinoma. The median age was 65 years (range 40-85) and histologic subtype was adenocarcinoma in 197 patients and squamous carcinoma in 74 patients. The treatment intent was radical in 182 and palliative in 89 patients. SUVmax was linked to histologic subtype (P = 0.008), tumor site (P = 0.01) and Union for International Cancer Control (UICC) stage (P < 0.001). On univariate analysis, prognosis was significantly associated with SUVmax (P = 0.001), T-stage (P < 0.001) and UICC stage (P < 0.001). On multivariate analysis, only T-stage and UICC stage remained significant. CONCLUSION: Pretreatment SUVmax was not a useful marker in isolation for determining prognosis of patients with esophageal carcinoma.
Authors: Claire Brown; Ben Howes; Glyn G Jamieson; Dylan Bartholomeusz; Urs Zingg; Thomas R Sullivan; Sarah K Thompson Journal: World J Surg Date: 2012-05 Impact factor: 3.352
Authors: Daniel Vallböhmer; Arnulf H Hölscher; Markus Dietlein; Elfriede Bollschweiler; Stephan E Baldus; Stefan P Mönig; Ralf Metzger; Harald Schicha; Matthias Schmidt Journal: Ann Surg Date: 2009-12 Impact factor: 12.969
Authors: Seung Hyup Hyun; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Su Jin Lee; Young Seok Cho; Ji Young Lee; Kyung-Han Lee; Byung-Tae Kim Journal: Ann Surg Oncol Date: 2009-10-14 Impact factor: 5.344
Authors: Marinke Westerterp; Gerrit W Sloof; Otto S Hoekstra; Fiebo J W Ten Kate; Gerrit A Meijer; Johannes B Reitsma; Ronald Boellaard; J Jan B van Lanschot; Carla F M Molthoff Journal: J Cancer Res Clin Oncol Date: 2007-07-25 Impact factor: 4.553
Authors: Heta Javeri; Lianchun Xiao; Eric Rohren; Jeffrey H Lee; Zhongxing Liao; Wayne Hofstetter; Dipen Maru; Manoop S Bhutani; Stephen G Swisher; Homer Macapinlac; Xuemei Wang; Jaffer A Ajani Journal: Cancer Date: 2009-11-15 Impact factor: 6.860
Authors: Boris Sepesi; Daniel P Raymond; Marek Polomsky; Thomas J Watson; Virginia R Litle; Carolyn E Jones; Rui Hu; Xing Qiu; Jeffrey H Peters Journal: J Gastrointest Surg Date: 2009-10-01 Impact factor: 3.452
Authors: Hyunjong Lee; Kyung Soo Lee; Yang Won Min; Hong Kwan Kim; Jae Ill Zo; Young Mog Shim; Joon Young Choi Journal: Front Oncol Date: 2022-06-30 Impact factor: 5.738